[How I treat relapsed/transformed follicular lymphoma].
作者信息
Xu B, Lin Z J
机构信息
Department of Hematology, the First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen 361003, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):983-988. doi: 10.3760/cma.j.issn.0253-2727.2023.12.003.
Abstract
摘要
相似文献
1
[How I treat relapsed/transformed follicular lymphoma].[我如何治疗复发/转化型滤泡性淋巴瘤]
Zhonghua Xue Ye Xue Za Zhi. 2023 Dec 14;44(12):983-988. doi: 10.3760/cma.j.issn.0253-2727.2023.12.003.
2
Management of relapsed/refractory follicular lymphoma.
Clin Adv Hematol Oncol. 2018 Apr;16 Suppl 10(4):1-12.
3
Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation.CD38表达对复发或难治性弥漫性大B细胞淋巴瘤及滤泡性淋巴瘤转化的预后影响
Leuk Lymphoma. 2022 Jun;63(6):1484-1487. doi: 10.1080/10428194.2021.2024820. Epub 2022 Jan 19.
4
Paraneoplastic peripheral blood eosinophilia in relapsed follicular lymphoma.
Leuk Lymphoma. 2011 Feb;52(2):328-30. doi: 10.3109/10428194.2010.532891. Epub 2010 Dec 6.
5
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.来那度胺和利妥昔单抗用于未经治疗的惰性淋巴瘤的安全性及活性：一项开放标签的2期试验
Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.
6
Rethinking Prognosis and Therapy for Follicular Lymphoma.滤泡性淋巴瘤预后与治疗的再思考
J Clin Oncol. 2015 Aug 10;33(23):2489-91. doi: 10.1200/JCO.2015.62.3256. Epub 2015 Jul 13.
7
Management of relapsed or refractory follicular lymphoma patients in daily practice - a French non-interventional study.日常实践中复发或难治性滤泡性淋巴瘤患者的管理——一项法国非干预性研究。
Leuk Lymphoma. 2018 Oct;59(10):2485-2488. doi: 10.1080/10428194.2018.1434878. Epub 2018 Feb 28.
8
Is there a role for bortezomib combinations in the management of patients with follicular lymphoma?硼替佐米联合用药在滤泡性淋巴瘤患者的治疗中是否有作用？
J Clin Oncol. 2011 Sep 1;29(25):3349-50. doi: 10.1200/JCO.2011.35.5586. Epub 2011 Aug 1.
9
Towards a chemotherapy-free approach in indolent lymphoma.惰性淋巴瘤的无化疗治疗方法探索
Lancet Oncol. 2014 Nov;15(12):1281-2. doi: 10.1016/S1470-2045(14)70488-7. Epub 2014 Oct 15.
10
Too much, or not enough? The enduring uncertainty of maintenance rituximab for transformed follicular lymphoma.
Leuk Lymphoma. 2021 Sep;62(9):2047-2049. doi: 10.1080/10428194.2021.1938033. Epub 2021 Jun 9.
本文引用的文献
1
Bispecific antibodies as monotherapy or in combinations for non-hodgkin B-cell lymphoma: latest updates from the American society of hematology 2022 annual meeting.双特异性抗体作为单药疗法或联合疗法用于非霍奇金B细胞淋巴瘤：美国血液学会2022年年会的最新进展
Exp Hematol Oncol. 2023 Apr 21;12(1):41. doi: 10.1186/s40164-023-00404-3.
2
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.ZUMA-1 的 5 年随访结果支持 axi-cel 在难治性大 B 细胞淋巴瘤中的治疗潜力。
Blood. 2023 May 11;141(19):2307-2315. doi: 10.1182/blood.2022018893.
3
Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial.瑞马卡布他基因自体白细胞介素（Carteyva）在中国复发/难治性滤泡性淋巴瘤成人患者中的初步疗效和安全性：一项I/II期临床试验。
Am J Hematol. 2022 Dec;97(12):E436-E438. doi: 10.1002/ajh.26711. Epub 2022 Sep 14.
4
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.在复发或难治性滤泡淋巴瘤患者中，双特异性抗体 mosunetuzumab 的安全性和疗效：一项单臂、多中心、2 期研究。
Lancet Oncol. 2022 Aug;23(8):1055-1065. doi: 10.1016/S1470-2045(22)00335-7. Epub 2022 Jul 5.
5
Adverse events in lymphoma patients treated with phosphoinositide 3 kinase Inhibitor in clinical trials: a meta-analysis.临床试验中接受磷酸肌醇 3 激酶抑制剂治疗的淋巴瘤患者的不良事件：一项荟萃分析。
Ann Hematol. 2022 Aug;101(8):1741-1753. doi: 10.1007/s00277-022-04876-x. Epub 2022 Jun 11.
6
Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.单独或联合 ASCT 使用 CAR T 细胞鸡尾酒治疗伴有 TP53 改变的侵袭性 B 细胞淋巴瘤的结果。
Signal Transduct Target Ther. 2022 Apr 11;7(1):101. doi: 10.1038/s41392-022-00924-0.
7
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.接受三线或三线以上系统治疗的复发或难治性滤泡淋巴瘤患者的治疗模式和结局（LEO CReWE）：一项多中心队列研究。
Lancet Haematol. 2022 Apr;9(4):e289-e300. doi: 10.1016/S2352-3026(22)00033-3.
8
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.替沙格赛定在成人复发或难治性滤泡性淋巴瘤中的应用：2期ELARA试验
Nat Med. 2022 Feb;28(2):325-332. doi: 10.1038/s41591-021-01622-0. Epub 2021 Dec 17.
9
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.阿基仑赛注射液治疗复发或难治性惰性非霍奇金淋巴瘤（ZUMA-5）：一项单臂、多中心、2 期临床试验。
Lancet Oncol. 2022 Jan;23(1):91-103. doi: 10.1016/S1470-2045(21)00591-X. Epub 2021 Dec 8.
10
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
Zotero 插件